The advent of anti–vascular endothelial growth factor (anti-VEGF) therapy has represented a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). However, anti-VEGF injections require frequent office visits for administration to maintain visual acuity gains, placing a considerable treatment burden on patients, caregivers, and the health care system. Achieving sustained efficacy with fewer injections has been a major focus of research into new therapeutic options for nAMD.
De La Huerta I, Kim SJ, Sternberg P. Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020;138(9):972–973. doi:10.1001/jamaophthalmol.2020.2723
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.